Spikevax (mRNA-1273) Variant-Containing Formulation

mRNA-1273 variant-containing vaccine formulation · Moderna, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Spikevax (mRNA-1273) Variant-Containing Formulation, covering 2026-03-16 to 2026-03-16. Get the full timeline:

Most recent: Clinical Trial Update: Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19 [Phase 4]

See pricing